Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

NEW YORK — Eurofins Scientific on Monday reported a 17 percent jump in revenues for fiscal year 2020, topping guidance provided in December.

Separately, the company announced that it has received Emergency Use Authorization from the US Food and Drug Administration for a direct-to-consumer version of its EmpowerDx COVID-19 Home Collection Kit.

Eurofins reported total FY2020 revenues of €5.44 billion ($6.55 billion) versus €4.56 billion the year before. The Luxembourg-based firm previously said it expected FY2020 revenues of €5.3 billion.

Eurofins attributed the growth to strong performance by its core business, particularly in Europe where revenues were up 24 percent to €3.15 billion from €2.50 billion a year earlier. Also contributing to the revenue increase was the more than €800 million generated in FY2020 from the sale of COVID-19 tests and reagents.

Included in those COVID-19 products is the EmpowerDx kit, a nasal swab specimen self-collection kit for SARS-CoV-2 testing that first received FDA EUA in October. Eurofins said the test, which is offered through its EmpowerDx subsidiary, has now been authorized by the FDA for sale to consumers without a prescription.

The firm noted that it made completed 26 acquisitions during the year, representing proforma annual revenues of €103 million.

Eurofins posted a FY2020 net profit of €540.5 million, or €2.75 per share, versus a profit of €195.3 million, or €1.05 per share, the year before. On an adjusted basis, its EPS were €3.63 for FY 2020.

Operating costs for the fiscal year grew nearly 11 percent to €4.09 billion from €3.73 billion.

At the end of FY2020, Eurofins had cash and cash equivalents totaling €912.4 million.

Looking ahead, the company said that it continues to expect revenues, excluding COVID-19-related revenues, of €5.45 billion for FY2021.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.